These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36775993)

  • 21. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
    Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
    Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece.
    Galani I; Souli M; Katsala D; Karaiskos I; Giamarellou H; Antoniadou A
    J Antimicrob Chemother; 2024 May; 79(5):1101-1108. PubMed ID: 38501368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, bla
    Johnston BD; Thuras P; Porter SB; Clabots C; Johnsona JR
    Diagn Microbiol Infect Dis; 2021 May; 100(1):115314. PubMed ID: 33578059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.
    Chandran S; Manokaran Y; Vijayakumar S; Shankar BA; Bakthavatchalam YD; Dwarakanathan HT; Yesudason BL; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):645-651. PubMed ID: 36905566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring
    Gaudereto JJ; Perdigão Neto LV; Leite GC; Ruedas Martins R; Boas do Prado GV; Rossi F; Guimarães T; Levin AS; Costa SF
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30783003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
    Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China.
    Zhou M; Cheng J; Liu Y; Hu Y; Liu Y; Lu J; Zhang S; Yu Y; Huang X; Yang Q; Liao K; Jin Y; Huang W; Feng X; Yang Q; Xu Y
    Clin Infect Dis; 2018 Nov; 67(suppl_2):S206-S216. PubMed ID: 30423043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    Liang R; Wang D; Hu M; Gu Y; Wang M; Hu D; Zhu M; Wang M
    J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.
    Dudoignon E; Caméléna F; Lafaurie M; Deniau B; Chaussard M; Coutrot M; Guillemet L; Cupaciu A; Pharaboz A; Boutin L; Benyamina M; Chaouat M; Mimoun M; Merimèche M; Mebazaa A; Plaud B; Berçot B; Dépret F; Mellon G
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1453-1459. PubMed ID: 38676856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
    Johnston BD; Thuras PD; Johnson JR
    Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115034. PubMed ID: 32331800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli.
    Li Y; Guo S; Li X; Yu Y; Yan B; Tian M; Xu B; Hu H
    Microb Pathog; 2022 May; 166():105517. PubMed ID: 35398467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of synergy between meropenem, gentamicin and sulbactam.
    Chaiben V; Yamada CH; Telles JP; de Andrade AP; Arend LNVS; Ribeiro VST; Dantas LR; Suss PH; Tuon FF
    J Antimicrob Chemother; 2022 May; 77(6):1676-1684. PubMed ID: 35368079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.